 Home > Active Ingredient News > Antitumor Therapy > AstraZeneca China reached a cooperation with Boan Biotechnology on bevacizumab injection

AstraZeneca China reached a cooperation with Boan Biotechnology on bevacizumab injection

 Last Update: 2021-06-03
 Source: Internet
 Author: User

Tags

fgf growth factor

a cabinets

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On May 26, AstraZeneca China announced that it has obtained the approval of Boyounuo (bevacizumab injection), an anti-tumor biological drug from Boan Bio, a subsidiary of Luye Pharmaceutical Group, in 21 provinces, cities, and autonomous regions in mainland China.

It is reported that bevacizumab injection is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets vascular endothelial growth factor (VEGF), which can inhibit its binding to VEGF receptors by binding to VEGF-A.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.